Buy Oxymorphone Online

Oxymorphone (sold under the brand names Numorphan and Opana among others) is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused.

It was developed in Germany in 1914. It was patented in 1955 and approved for medical use in 1959. In June 2017 the FDA asked Endo Pharmaceuticals to remove its product from the US market. This was in part due to the opioid epidemic in the US, and the fact that a 2012 reformulation failed to stop illicit injection of the drug. Endo responded by voluntarily removing Opana ER from the market a month later. Generic versions of extended-release oxymorphone, such as those manufactured by Amneal Pharmaceuticals, are still available in the US.

Medical uses

Oxymorphone Immediate Release relieves moderate to severe pain, such as treating acute post-surgical pain. For any chronic treatment of pain, clinicians should only consider long term use if there is significant clinical benefit to the patient’s therapy that outweigh any potential risk. The first line treatment choices for chronic pain are non-pharmacological and non-opioid agents.

Oxymorphone extended-release tablets manage chronic pain and are suitable for individuals already using strong opioids regularly for an extended duration. Immediate-release oxymorphone tablets serve as recommended options for breakthrough pain in individuals using the extended-release version. Compared to other opioids, oxymorphone has similar pain relieving efficacy.

Availability

Brands and forms

Endo Pharmaceuticals marketed Oxymorphone under the brand names Opana and Opana ER. The manufacturer withdrew Opana ER in 2017 in response to an FDA request, rendering it unavailable in the US. However, various manufacturers offer both immediate release (IR) and extended release (ER) formulations under the generic names Oxymorphone and Oxymorphone ER.

Oxymorphone is also available as an injectable for inpatient use, available for IV (intravenous), IM (intramuscular), and SC (subcutaneous) injection.

A commonly used modified-release dosage form known as extended release (ER) alters the pharmacokinetics of the drug.

Oral dosage forms

Oxymorphone comes in a variety of doses.